Current approaches of nanomedicines in the market and various stage of clinical translation.
10.1016/j.apsb.2022.02.025
- Author:
Xiaoting SHAN
1
;
Xiang GONG
1
;
Jie LI
1
;
Jingyuan WEN
2
;
Yaping LI
1
;
Zhiwen ZHANG
1
Author Information
1. State Key Laboratory of Drug Research & Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
2. School of Pharmacy, University of Auckland, Auckland 1142, New Zealand.
- Publication Type:Review
- Keywords:
Clinical translations;
Disease-driven design;
Liposomes;
Marketed products;
Nanomedicines;
Nanoparticles;
Quality by design;
Vaccines
- From:
Acta Pharmaceutica Sinica B
2022;12(7):3028-3048
- CountryChina
- Language:English
-
Abstract:
Compared with traditional drug therapy, nanomedicines exhibit intriguing biological features to increase therapeutic efficiency, reduce toxicity and achieve targeting delivery. This review provides a snapshot of nanomedicines that have been currently launched or in the clinical trials, which manifests a diversified trend in carrier types, applied indications and mechanisms of action. From the perspective of indications, this article presents an overview of the applications of nanomedicines involving the prevention, diagnosis and treatment of various diseases, which include cancer, infections, blood disorders, cardiovascular diseases, immuno-associated diseases and nervous system diseases, etc. Moreover, the review provides some considerations and perspectives in the research and development of nanomedicines to facilitate their translations in clinic.
